LGLusiele Guaraldo

Lusiele Guaraldo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lusiele Guaraldo has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cerebral venous thrombosis in non-bacterial infections: a systematic review

    by Matheus Campos Medeiros, Ezequias Batista Martins, Lusiele Guaraldo, Guilherme Amaral Calvet

    This systematic review summarizes evidence on cerebral venous thrombosis (CVT) following non-bacterial (viral, fungal, parasitic) infections, excluding COV

  • Open Access

    Viral, Clinical, and Epidemiological Characteristics of Oropouche Fever in Southeastern Brazil

    by Ezequias Batista Martins, Otilia Lupi, Otávio Melo Espíndola, Fernanda de Bruycker-Nogueira, Ighor Arantes, Clarisse da Silveira Bressan, Anielle de Pina-Costa, Michele Fernanda Borges da Silva, Tulio Vieira Mendes, Rogério Valls de Souza, et al.

    Oropouche virus (OROV), an arbovirus causing acute febrile illness, was mostly restricted to the Amazon basin until 2023, when a reassortant lineage spread across Latin America. Increasing numbers of cases have subsequently been reported in extra-Amazonian regions of Brazil. However, follow-up and detailed clinical description is limited. This study aimed to describe viral, clinical, and epidemiological characteristics of OROV cases in the Brazilian states of Rio de Janeiro and Minas Gerais. This longitudinal study enrolled adults with OROV exposure. Clinical and laboratorial data were assessed, and serum, urine, and saliva samples were tested for OROV RNA and sequenced. From December 2024 to May 2025, 55 OROV cases were recruited (median age: 46, 65% female). The novel OROV reassortant was confirmed by RNA sequencing. The acute phase was characterized by headache (87%), malaise (87%), fever (82%), myalgia (75%), and rash (45%). Recurrence of symptoms occurred in one-third of participants, including malaise (53%), fever (41%), arthralgia (41%), and chills (41%), but without resurgence of viral load. Viral RNA in serum and saliva was primarily detected in the first week of disease, and beyond the third week in urine. Cases appeared in clusters and rash was frequently observed. Symptoms returned after 1 week, indicating the importance of patient follow-up. Cases either lived near banana plantations or participated in recreational activities at waterfalls, raising concerns about ecotourism in the Atlantic Forest. Since OROV RNA was detectable in urine for a prolonged period, urine samples may be useful for diagnosis.


  • Open Access

    Use of Digital Tools in Arbovirus Surveillance: Scoping Review

    by Carolina Lopes Melo, Larissa Rangel Mageste, Lusiele Guaraldo, Daniela Polessa Paula, Mayumi Duarte Wakimoto

    Background: The development of technology and information systems has led to important changes in public health surveillance. Objective: This scoping review aimed to assess the available evidence and gather information about the use of digital tools for arbovirus (dengue virus [DENV], zika virus [ZIKV], and chikungunya virus [CHIKV]) surveillance. Methods: The databases used were MEDLINE, SCIELO, LILACS, SCOPUS, Web of Science, and EMBASE. The inclusion criterion was defined as studies that described the use of digital tools in arbovirus surveillance. The exclusion criteria were defined as follows: letters, editorials, reviews, case reports, series of cases, descriptive epidemiological studies, laboratory and vaccine studies, economic evaluation studies, and studies that did not clearly describe the use of digital tools in surveillance. Results were evaluated in the following steps: monitoring of outbreaks or epidemics, tracking of cases, identification of rumors, decision-making by health agencies, communication (cases and bulletins), and dissemination of information to society). Results: Of the 2227 studies retrieved based on screening by title, abstract, and full-text reading, 68 (3%) studies were included. The most frequent digital tools used in arbovirus surveillance were apps (n=24, 35%) and Twitter, currently called X (n=22, 32%). These were mostly used to support the traditional surveillance system, strengthening aspects such as information timeliness, acceptability, flexibility, monitoring of outbreaks or epidemics, detection and tracking of cases, and simplicity. The use of apps to disseminate information to society (P=.02), communicate (cases and bulletins; P=.01), and simplicity (P=.03) and the use of Twitter to identify rumors (P=.008) were statistically relevant in evaluating scores. This scoping review had some limitations related to the choice of DENV, ZIKV, and CHIKV as arboviruses, due to their clinical and epidemiological importance. Conclusions: In the contemporary scenario, it is no longer possible to ignore the use of web data or social media as a complementary strategy to health surveillance. However, it is important that efforts be combined to develop new methods that can ensure the quality of information and the adoption of systematic measures to maintain the integrity and reliability of digital tools’ data, considering ethical aspects.


  • Open Access

    Use of Digital Tools in Arbovirus Surveillance: Scoping Review (Preprint)

    by Carolina Lopes Melo, Larissa Rangel Mageste, Lusiele Guaraldo, Daniela Polessa Paula, Mayumi Duarte Wakimoto

    BACKGROUND The development of technology and information systems has led to important changes in public health surveillance. OBJECTIVE This scoping review aimed to assess the available evidence and gather information about the use of digital tools for arbovirus (dengue virus [DENV], zika virus [ZIKV], and chikungunya virus [CHIKV]) surveillance. METHODS The databases used were MEDLINE, SCIELO, LILACS, SCOPUS, Web of Science, and EMBASE. The inclusion criterion was defined as studies that described the use of digital tools in arbovirus surveillance. The exclusion criteria were defined as follows: letters, editorials, reviews, case reports, series of cases, descriptive epidemiological studies, laboratory and vaccine studies, economic evaluation studies, and studies that did not clearly describe the use of digital tools in surveillance. Results were evaluated in the following steps: monitoring of outbreaks or epidemics, tracking of cases, identification of rumors, decision-making by health agencies, communication (cases and bulletins), and dissemination of information to society). RESULTS Of the 2227 studies retrieved based on screening by title, abstract, and full-text reading, 68 (3%) studies were included. The most frequent digital tools used in arbovirus surveillance were apps (n=24, 35%) and Twitter, currently called X (n=22, 32%). These were mostly used to support the traditional surveillance system, strengthening aspects such as information timeliness, acceptability, flexibility, monitoring of outbreaks or epidemics, detection and tracking of cases, and simplicity. The use of apps to disseminate information to society (P=.02), communicate (cases and bulletins; P=.01), and simplicity (P=.03) and the use of Twitter to identify rumors (P=.008) were statistically relevant in evaluating scores. This scoping review had some limitations related to the choice of DENV, ZIKV, and CHIKV as arboviruses, due to their clinical and epidemiological importance. CONCLUSIONS In the contemporary scenario, it is no longer possible to ignore the use of web data or social media as a complementary strategy to health surveillance. However, it is important that efforts be combined to develop new methods that can ensure the quality of information and the adoption of systematic measures to maintain the integrity and reliability of digital tools’ data, considering ethical aspects.

  • Open Access

    Frailty and health-related quality of life among older people living with HIV pre- and post-COVID-19 pandemic onset: A cross-sectional study

    by Thiago S. Torres, Jovanice S. Jesus, Daniel Arabe, Lusiele Guaraldo, Fabião A. Meque, Flavia Serrao Lessa, Lívia Dumont Facchinetti, Rita Estrela, Valdilea G. Veloso, Beatriz Grinsztejn, et al.


  • Open Access

    Cohort profile: follow-up of a household cohort throughout five epidemic waves of SARS-CoV-2 in Rio de Janeiro, Brazil

    by Michele Fernanda Borges da Silva, Lusiele Guaraldo, Heloisa Ferreira Pinto Santos, Leonardo Soares Bastos, Anielle de Pina-Costa, Stephanie Lema Suarez Penetra, Isabella Campos Vargas de Moraes, Guilherme Amaral Calvet, Trevon Louis Fuller, Paola Cristina Resende Silva, et al.

    Since May 2020, we have been conducting a comprehensive study to understand the natural history of SARS-CoV-2 infection in Rio de Janeiro, Brazil. Our focus has been on following families, systematically collecting respiratory tract swabs and blood samples, monitoring symptoms, and gathering data on vaccine status. This paper aims to describe the household cohort across five epidemic waves of SARS-CoV-2, providing an overview of the collected data and a description of the epidemiological, clinical, and immunological characteristics and incidence of SARS-CoV-2 infection. Our cohort includes 691 participants from 189 households. During the five epidemic waves, we detected 606 infections. The incidence density of SARS-CoV-2 infection ranged from 4 (Delta) to 56 (B.1.1.33) per 1,000 person-week, with a peak in wave B.1.1.33 in all age groups. The seroprevalence of SARS-CoV-2 antibodies (IgG anti spike protein) varied from 37%, in the pre-VoC period, to 99%, in the Omicron period, progressively increasing after each wave in a similar manner regardless of age. As we have monitored the cohort continuously since the beginning of the pandemic, we were able to collect data across different scenarios according to the predominant lineage in circulation. Via active monitoring of families, we were able to carry out an epidemiological surveillance on SARS-CoV-2, including its variants, persistence of symptoms, and changes in immunity over time in the population, contributing to knowledge of the natural history of SARS-CoV-2 infection.


  • Open Access

    Pharmacotherapeutic profile, polypharmacy and its associated factors in a cohort of people living with HIV in Brazil

    by Robson Pierre Nascimento da Silva, Luana M. S. Marins, Lusiele Guaraldo, Paula Mendes Luz, Sandra W. Cardoso, Ronaldo I. Moreira, Vanessa da Gama Oliveira, Valdilea G. Veloso, Beatriz Grinsztejn, Rita Estrela, et al.

    Background: The increased survival provided by the access, development, and evolution of antiretroviral drugs (ARV) greatly increased the life expectancy of people living with HIV (PWH). This has also led to an increased occurrence of diseases or morbidities related to aging. In individuals with multiple comorbidities, the simultaneous use of multiple medications, also known as polypharmacy, is common, and rational use of medications is essential. This study aims to describe the pharmacotherapeutic profile, estimate the prevalence of polypharmacy and identify factors associated with polypharmacy in a cohort of adult PWH from a referral unit in Rio de Janeiro, Brazil. Methods: Cross-sectional study including PWH on ARV who received at least one medical prescription (outpatient/hospitalized) in 2019. We described the proportion of prescribed medications according to ARV and Anatomical Therapeutic Chemical (ATC) classes stratified by age (< 50 vs. ≥50 years). Polypharmacy was defined as ≥ 5 medications prescribed beyond ARV. Logistic regression models assessed demographic and clinical factors associated with polypharmacy. Results: A total of 143,306 prescriptions of 4547 PWH were analyzed. Median age was 44.4 years (IQR:35.4–54.1) and 1615 (35.6%) were ≥ 50 years. A total of 2958 (65.1%) participants self-identified as cisgender man, 1365 (30.0%) as cisgender woman, and 224 (4.9%) as transgender women. Most self-declared Black/Pardo (2582; 65.1%) and 1984 (44.0%) completed elementary education or less. Median time since HIV diagnosis was 10.9 years (IQR:6.2–17.7). Most frequently prescribed concomitant medications were nervous system (64.8%), antiinfectives for systemic use (60.0%), alimentary tract and metabolism (45.9%), cardiovascular system (40.0%) and respiratory system (37.1%). Prevalence of polypharmacy was 50.6% (95%CI: 49.2–52.1). Model results indicated that being older, self-identify as cisgender woman, having less education and longer time since HIV diagnosis increased the odds of polypharmacy. Conclusions: We found high rates of polypharmacy and concomitant medication use in a cohort of PWH in Brazil. Targeted interventions should be prioritized to prevent interactions and improve treatment, especially among individuals using central nervous system and cardiovascular medications, as well as certain groups such as cisgender women, older individuals and those with lower education. Standardized protocols for continuous review of patients’ therapeutic regimens should be implemented.


  • Open Access

    Guidelines for organization, operation and evaluation of clinical trials pharmacies in Brazil: a scope review

    by Valeria Rita Teixeira Ribeiro, Luana Monteiro Spindola Marins, Ana Carolina Vitorino Vieira, Debora Santana Geraldo, Giovanna Giannini Costa, Renata Bastos de Araujo, Robson Pierre Nascimento da Silva, Lusiele Guaraldo, Thiago Silva Torres

    The development of new drugs depends on several scientific steps, which culminate in clinical trials. The clinical trials pharmacy (CTP) is the place for receiving, preparing, storing and dispensing the investigational product or study drug. Therefore, it must have infrastructure and procedures that guarantee participant safety and quality of research data. This study aimed to systematize guidelines for CTP in Brazil. We conducted a scope review and organized the results using the Ishikawa Method (6Ms). In total, 51 publications were selected for each “M”, 39 laws, regulations or guidelines and 12 scientific articles: 25 publications for pharmaceutical services (pharmacy procedures to ensure participant safety from investigational product ordering to final disposition), 14 for Quality Indicators, 12 for Human Resources, 11 for Infrastructure, 11 for Material Resources and 5 for Investigational Product. Our results synthesize information for the organization, operation and evaluation of CTP in Brazil, emphasizes the inclusion of the pharmacist within the clinical trials context, and contributes to preparation for monitoring, auditing, and inspections conducted by regulatory agencies.

  • Open Access

    Diretrizes para organização, funcionamento e avaliação de farmácias de ensaios clínicos no Brasil: revisão de escopo

    by Valeria Rita Teixeira Ribeiro, Luana Monteiro Spindola Marins, Ana Carolina Vitorino Vieira, Debora Santana Geraldo, Giovanna Giannini Costa, Renata Bastos de Araujo, Robson Pierre Nascimento da Silva, Lusiele Guaraldo, Thiago Silva Torres

    Resumo O desenvolvimento de novos medicamentos depende de etapas científicas que culminam nos ensaios clínicos em seres humanos. A farmácia de ensaios clínicos (FEC) é o local destinado ao recebimento, preparação, armazenamento e dispensação do produto investigacional (PI). Para tanto, deve possuir infraestrutura e procedimentos que garantam a segurança do participante e a qualidade da pesquisa. Este trabalho teve por objetivo sistematizar diretrizes para FEC no Brasil. Foi realizada uma revisão de escopo e as diretrizes foram organizadas utilizando o método de Ishikawa (“método 6Ms”). No total foram selecionadas 51 publicações, sendo 39 diretrizes e normas e 12 artigos científicos para cada “M”; 25 descreveram o ciclo de assistência farmacêutica (procedimentos para assegurar a segurança dos participantes, desde a requisição do produto até a destinação final), 14 indicadores de qualidade, 12 de recursos humanos, 11 de infraestrutura e recursos materiais e 5 descreveram PIs. para organização, funcionamento e avaliação de FEC no Brasil e corroboram a necessidade da presença do profissional farmacêutico no ciclo da assistência farmacêutica no contexto dos ensaios clínicos, contribuindo ainda na preparação para monitorias, auditorias e inspeções de agências regulatórias.


  • Open Access

    Óbitos por eventos adversos a medicamentos no Brasil: Sistema de Informação sobre Mortalidade como fonte de informação

    by Ana Cristina Marques Martins, Fabíola Giordani, Mariana de Castro Gonçalves, Lusiele Guaraldo, Suely Rozenfeld

    Os eventos adversos a medicamentos (EAM) são danos aos pacientes relacionados ao uso de medicamentos, parte dos quais pode levar à morte. Os registros de óbitos são fonte importante de informação, quando se empregam os códigos da 10ª revisão da Classificação Internacional de Doenças (CID-10) sugestivos de EAM. O estudo identificou os EAM registrados no Sistema de Informação sobre Mortalidade (SIM), analisando sua distribuição por ano, faixa etária e tipo de evento. Trata-se de um estudo ecológico com coleta de dados retrospectiva de identificação de EAM no SIM, por meio dos códigos da CID-10. O estudo compreendeu óbitos ocorridos no Brasil, de 2008 a 2016. Houve aumento nas proporções de óbitos associados aos EAM de 2008 a 2016, com taxa de mortalidade por 1 milhão de habitantes indo de 8,70 para 14,40 no período. A maioria dos eventos correspondeu aos transtornos mentais e comportamentais em razão do uso de psicofármacos. A maioria dos óbitos (12.311) relacionados a códigos de EAM foram identificados em diversos capítulos da CID-10. Já o capítulo XX, específico para eventos adversos, permitiu identificar parcela menor de óbitos (4.893). As maiores taxas de eventos ocorreram entre indivíduos com 60 anos ou mais (39,8/1 milhão) e crianças menores de um ano (22,0/1 milhão). A identificação de óbitos associados aos EAM, por meio do SIM, constitui uma estratégia importante para a abordagem dos eventos indesejáveis relacionados aos medicamentos. Os óbitos relacionados ao uso de psicofármacos foram os de maior frequência e os idosos foram a faixa etária mais acometida por EAM.